-
-
-
-
-
-
-
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
-
-
-
-
-
-
-
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
-
-
-
-
-
-
-
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
-
-
-
-
-
-
-
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) Reports Q2 Results
-
-
-
-
-
-
-
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

